Background The consequences of influenza in the elderly (those age 65 years or older) are
complications, hospitalisations, and death. The primary goal of influenza vaccination in the …

Interest in intranasal (IN) administration as a non-invasive route for drug delivery continues
to grow rapidly. The nasal mucosa offers numerous benefits as a target issue for drug …

Context Influenza and respiratory syncytial virus (RSV) cause substantial morbidity and
mortality. Statistical methods used to estimate deaths in the United States attributable to …

BACKGROUND Since the 1998 European Respiratory Society (ERS) lower respiratory tract
infection (LRTI) guidelines 1 were published, the evidence on which they were based has …

Influenza virus is a globally important respiratory pathogen which causes a high degree of
morbidity and mortality annually. The virus is continuously undergoing antigenic change and …

Influenza vaccination policy in most high-income countries attempts to reduce the mortality
burden of influenza by targeting people aged at least 65 years for vaccination. However, the …

Background Influenza-associated morbidity and mortality has not decreased in the last
decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza …

Background Influenza vaccinations are currently recommended in the care of people with
COPD, but these recommendations are based largely on evidence from observational …

Pneumonia in the elderly is a common and serious problem with a clinical presentation that
can differ from that in younger patients. Older patients with pneumonia complain of …

Context Influenza virus is a major cause of illness, disruption to daily life, and increased use
of health care in all age groups. Objective To assess the safety and effectiveness of …